In using human glioma xenograft models with patient-derived tumors in [NSG NOD-scid IL2Rgammanull] mice, we previously found that IL13BBζ-CAR T cells improved anti-tumor activity and T cell persistence as compared to first-generation IL13ζ-CAR CD8(+) T cells that had shown evidence for bioactivity in patients (21). The gene discussed is CD8A; the disease is glioma.